| Identification | More | [Name]
Tibolone | [CAS]
5630-53-5 | [Synonyms]
17ALPHA-HYDROXY-7ALPHA-METHYL-19-NORPREGN-5(10)-EN-20-YN-3-ONE
17-hydroxy-7alpha-methyl-19-norpregn-5(10)-en-20-yn-3-one
19-NORPREGN-5(10)-EN-20-YN-3-ONE,17-HYDROXY-7-METHYL-, (7A,17A)-
5(10)-ESTREN-7-ALPHA-METHYL-17-ALPHA-ETHYNYL-17-BETA-OL-3-ONE
(7A,17A)-17-HYDROXY-7-METHYL-19-NORPREGN-5(10)-EN-20-YL-3-ONE
LIVIAL
LIVIELLA
TIBOLONE
17β-Hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-ene-20-yn-3-one
(7a,17a)-17-Hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
7a-Methyl-17a-ethynyl-17-hydroxy-5(10)-estren-3-one
7a-Methyl-5,10-norethindrone
Org OD 14
(7α,17α)-17-Hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one
19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7alpha,17alpha)-
7a-Methyl-17a-ethynyl-17b-hydroxy-5(10)-estren-3-one
7a-Methyl-D5,10-norethindrone | [EINECS(EC#)]
227-069-1 | [Molecular Formula]
C21H28O2 | [MDL Number]
MFCD00864178 | [Molecular Weight]
312.45 | [MOL File]
5630-53-5.mol |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
169 °C | [Boiling point ]
447.4±45.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [refractive index ]
105 ° (C=0.54, CH2Cl2/Et2O) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble15mg/mL, clear | [form ]
neat | [pka]
13.10±0.60(Predicted) | [color ]
white to beige | [Usage]
A synthetic steroid with weak estrogenic, androgenic and progestogenic activity. A pharamceutical used in the treatment of menopausal syndrome | [Merck ]
9427 | [InChI]
InChI=1/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/s3 | [InChIKey]
WZDGZWOAQTVYBX-PGFZCDQENA-N | [SMILES]
[C@@]12([H])[C@H](C)CC3CC(=O)CCC=3[C@@]1([H])CC[C@]1(C)[C@](CC[C@@]21[H])(O)C#C |&1:0,2,12,16,18,21,r| | [CAS DataBase Reference]
5630-53-5(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
N | [Risk Statements ]
R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes .
S61:Avoid release to the environment. Refer to special instructions safety data sheet . | [RIDADR ]
UN 3077 9/PG 3 | [RTECS ]
RC8964020 |
| Hazard Information | Back Directory | [Description]
Tibolone is a synthetic steroid with weak progestational and estrogenic properties,
reportedly useful in controlling symptoms resulting from natural or surgical menopause.
It has thus far shown no significant antithrombotic effect in post-menopausal patients. | [Chemical Properties]
White Solid | [Originator]
Akzo (Organon) (The Netherklands) | [Uses]
A synthetic steroid with weak estrogenic, androgenic and progestogenic activity. A pharamceutical used in the treatment of menopausal syndrome | [Definition]
ChEBI: Estran-3-one with a double bond between positions 5 and 10, and bearing both an ethynyl group and a hydroxy group at position 17 (R-configuration). A synthetic steroid hormone drug which acts as an agonist at all five type I steroid hormon
receptors, it is used in the prevention of postmenopausal osteoporosis and for treatment of endometriosis. | [Brand name]
Livial | [Pharmacokinetics]
Raloxifene is rapidly absorbed following oral administration, with an estimated 60% absorption, but it has a
very low bioavailability (2%), associated with extensive phase II metabolism. The metabolites are excreted via
the bile, with potential enterohepatic recycling that could account for the interaction with cholestyramine.
Supportive of the enterohepatic recycling is the half-life of 28 hours. Metabolism of raloxifene occurs to a great
extent in the intestine and consists of glucuronide conjugation catalyzed by uridine diphosphate
glucuronosyltransferase (UGT). | [Clinical Use]
Tibolone is a synthetic steroid that has been shown to increase bone mineral density similar to
alendronate. The U.S. FDA approval is pending; overseas, this agent is used for the treatment of
menopausal symptoms as well as the prevention of osteoporosis. It is considered to be a viable
alternative to conjugated equine estrogen plus micronized progesterone. | [Side effects]
The most common reason for
patient withdrawal from clinical trials was vaginal bleeding (also a common side effect when estrogen
therapy is used). |
|
|